Zafgen, Inc. (ZFGN) Reaches $5.56 52-Week High; Steris Plc (STE) Covered By 3 Bullish Analysts Last Week

January 14, 2018 - By Richard Conner

The stock of Zafgen, Inc. (NASDAQ:ZFGN) hit a new 52-week high and has $5.89 target or 6.00% above today’s $5.56 share price. The 7 months bullish chart indicates low risk for the $152.84M company. The 1-year high was reported on Jan, 14 by Barchart.com. If the $5.89 price target is reached, the company will be worth $9.17M more. The stock decreased 0.71% or $0.04 during the last trading session, reaching $5.56. About 111,654 shares traded or 5.61% up from the average. Zafgen, Inc. (NASDAQ:ZFGN) has declined 36.39% since January 14, 2017 and is downtrending. It has underperformed by 53.09% the S&P500.

Among 5 analysts covering Steris (NYSE:STE), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Steris had 9 analyst reports since November 2, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, June 3 by Northcoast. Raymond James maintained Steris Plc (NYSE:STE) on Wednesday, August 9 with “Outperform” rating. KeyBanc Capital Markets maintained the stock with “Buy” rating in Thursday, November 2 report. The rating was maintained by KeyBanc Capital Markets with “Buy” on Tuesday, October 17. The rating was initiated by Goldman Sachs on Wednesday, November 30 with “Neutral”. The stock has “Market Perform” rating by Raymond James on Wednesday, January 3. Raymond James maintained the shares of STE in report on Monday, October 16 with “Outperform” rating. See Steris Plc (NYSE:STE) latest ratings:

03/01/2018 Broker: Raymond James Old Rating: Outperform New Rating: Market Perform Old Target: $100 Downgrade
02/11/2017 Broker: KeyBanc Capital Markets Rating: Buy New Target: $101.0 Maintain
17/10/2017 Broker: KeyBanc Capital Markets Rating: Buy New Target: $91.0 Maintain
16/10/2017 Broker: Raymond James Rating: Outperform Old Target: $95 New Target: $100 Maintain
09/08/2017 Broker: Raymond James Rating: Outperform Old Target: $90 New Target: $95 Maintain

STERIS plc develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support services and products for healthcare, pharmaceutical, scientific, research, industrial, and governmental clients worldwide. The company has market cap of $7.80 billion. The companyÂ’s Healthcare Products segment offers steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers, as well as liquid chemical sterilant processing systems; automated washer/disinfector systems; general and specialty surgical tables, surgical and examination lights, equipment management systems, operating room storage cabinets, warming cabinets, scrub sinks, and other accessories; and gastrointestinal devices and accessories. It has a 54.66 P/E ratio. It also provides OR integration, OR and sterile processing department, workflow, patient tracking, and instrument management solutions; and cleaning chemistries and sterility assurance products.

Investors sentiment decreased to 0.5 in Q3 2017. Its down 0.50, from 1 in 2017Q2. It turned negative, as 3 investors sold Steris Plc shares while 3 reduced holdings. 2 funds opened positions while 1 raised stakes. 137,131 shares or 66.30% less from 406,945 shares in 2017Q2 were reported. Citigroup reported 2,339 shares stake. Ghp Inv Advsrs Inc invested 0.26% in Steris Plc (NYSE:STE). Gotham Asset Management Ltd Co holds 0.07% or 55,355 shares in its portfolio. Hanson Doremus Invest Management owns 1,500 shares or 0.05% of their US portfolio. Shell Asset Company holds 36,726 shares or 0.03% of its portfolio. Alphamark Advisors owns 0.01% invested in Steris Plc (NYSE:STE) for 150 shares. Fruth Mgmt reported 15,076 shares stake. The Illinois-based Prudential Public Limited Co has invested 0% in Steris Plc (NYSE:STE).

The stock increased 1.37% or $1.24 during the last trading session, reaching $91.67. About 263,325 shares traded. Steris Plc (NYSE:STE) has risen 7.97% since January 14, 2017 and is uptrending. It has underperformed by 8.73% the S&P500.

Among 8 analysts covering Zafgen Inc (NASDAQ:ZFGN), 2 have Buy rating, 0 Sell and 6 Hold. Therefore 25% are positive. Zafgen Inc has $60 highest and $5 lowest target. $24.67’s average target is 343.71% above currents $5.56 stock price. Zafgen Inc had 18 analyst reports since August 25, 2015 according to SRatingsIntel. SunTrust maintained the shares of ZFGN in report on Monday, October 19 with “Buy” rating. The rating was downgraded by Cowen & Co to “Market Perform” on Wednesday, July 20. The rating was upgraded by RBC Capital Markets on Thursday, January 21 to “Outperform”. Cowen & Co maintained it with “Buy” rating and $60 target in Tuesday, August 25 report. As per Thursday, October 15, the company rating was maintained by FBR Capital. RBC Capital Markets maintained Zafgen, Inc. (NASDAQ:ZFGN) on Thursday, October 15 with “Outperform” rating. The firm earned “Mkt Outperform” rating on Friday, January 6 by JMP Securities. The rating was downgraded by Suntrust Robinson on Thursday, December 3 to “Neutral”. JMP Securities downgraded the shares of ZFGN in report on Monday, October 19 to “Mkt Perform” rating. The stock of Zafgen, Inc. (NASDAQ:ZFGN) has “Sector Perform” rating given on Wednesday, December 2 by RBC Capital Markets.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>